Drug Trial Radar · NCT07080775
The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
39
Actual
Start
Aug 5, 2025
Primary completion
Jul 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- XellSmart Therapeutics (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Beijing Tiantan Hospital
- First posted
- Jul 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease. This Phase II clinical trial is designed to evaluate the safety, tolerability and Efficacy of XS411 (derived dopaminergic neural progenitor cell injection) in patients with Parkinson's disease.
Conditions
- Parkinson's Disease
Interventions
human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injectionBiological
5.0×10\^7 cells/mL, injection, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of XS411CN in treatment of primary Parkinson's diseaseTime frame: 28 days after administration of XS411CN
- MDS-UPDRS Part III score during the 'OFF' stateTime frame: Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.